(Press-News.org) CHICAGO, IL (May 30, 2014)—More than a quarter of HIV+ patients are also infected with the Hepatitis C virus (HCV), which may complicate treatment and care decisions after a cancer diagnosis. The specifics of those complications haven't been well-researched in the past. Results from a new Fox Chase Cancer Center study on this patient population may start filling in that gap.
Fox Chase Hematologist and Medical Oncologist Stefan K. Barta, MD, MS, MRCP – who led the study – analyzed data from HIV+ patients diagnosed with lymphoma, collected over 17 years, to better understand how HCV infection influences survival outcomes. Dr. Barta's collaborators will present the group's findings at the 50th Annual Meeting of the American Society of Clinical Oncology.
Reactivation of HCV, in which the virus is detectable but not necessarily causing symptoms, is common in HIV+ patients. Notably, Dr. Barta and his team found that reactivation of HCV did not appear to worsen survival outcomes for lymphoma patients who also had HIV.
"Many patients do experience some reactivation of the Hepatitis C virus, but in most patients it seems to be self-limited and does not affect outcomes for cancer treatment," said Dr. Barta.
He noted that treating lymphoma patients co-infected with HIV and HCV requires caution and care. HIV more than triples the risk of liver failure in individuals also infected with HCV, according to the Centers for Disease Control and Prevention. And among cancer patients, HIV+ patients infected with HCV can fall into a feedback loop that may lessen the effectiveness of treatment.
"Patients undergoing chemotherapy can experience reactivation of the Herpes C virus, which in turn can lead to liver failure," said Dr. Barta. "This means we have to dose-reduce chemotherapy, which could negatively affect outcomes."
In addition, HIV+ patients often take a host of other medications, including antiretrovirals, which makes them especially vulnerable to side effects like toxicity. However, Dr. Barta said the new study suggests the potential risks shouldn't deter oncologists from treating these patients with chemotherapy.
"People should not be scared of treating patients with HIV and HCV aggressively," said Dr. Barta. "At the same time, we have to be careful and cautious to monitor those patients because reactivation does occur and could potentially lead to severe liver failures."
He and his colleagues analyzed the medical records of 190 HIV+ patients who had been diagnosed with lymphoma at the Albert Einstein Cancer Center in Bronx, New York, from 1997 to 2013. Patients with primary central nervous system lymphomas were excluded. The researchers found that 53 patients, or 28 percent, of eligible patients were also infected with HCV. The virus reactivated in 17 of those patients, or about one-third of the patient population infected with HCV, during treatment.
Patients infected with HCV had an overall survival of 59.7 months, compared to 88.6 months for patients with neither HCV nor Hepatitis B Virus (HBV). However, that survival advantage vanished when the researchers adjusted for variables including age, sex, race, CD4 count, presence of cirrhosis, type of lymphoma, and levels of LDH (lactate dehydrogenase, an enzyme). The multivariate analysis showed that co-infection with HCV was not associated with lower overall survival in lymphoma patients. At the same time, the researchers did find worse overall survival outcomes associated with low CD4 count (below 100 cells/cubic millimeter), a diagnosis of non-Hodgkin lymphoma, advanced stage disease, LDH levels over 190, or cirrhosis.
Dr. Barta said he hopes the new study opens cancer clinical trials to an understudied patient population. HIV+ patients with HCV are often excluded from cancer clinical trials because of concerns about liver failure and drug toxicity, arising from the interaction of retroviral medications with chemotherapy. Barta says he hopes the new findings, which suggest these patients can tolerate chemotherapy without adverse outcomes, will help reverse that trend.
"This is really important for a large proportion of patients," he said. "We want to assure researchers that these patients, as long as they have adequate liver function, should also be enrolled in clinical trials."
INFORMATION:
Dr. Barta's coauthors include Ashwin Sridharan, Santiago Aparo, Susanna A. Curtis, and Justin D. Kaner.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation's first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center's nursing program has received the Magnet status for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, visit Fox Chase's Web site at http://www.foxchase.org or call 1-888-FOX CHASE or (1-888-369-2427). END
Hepatitis C reactivation doesn't worsen survival for HIV+ patients diagnosed with lymphoma
2014-05-30
ELSE PRESS RELEASES FROM THIS DATE:
Identification of central nervous system involvement for patients with AIDS-related lymphomas
2014-05-30
CHICAGO, IL (May 30, 2014)—Patients with AIDS-related lymphomas (ARL) may face an increased risk of central nervous system involvement (CNSi) compared to other lymphomas. The effect of CNSi on survival outcomes, however, hasn't been thoroughly examined until now.
In a new study led by Fox Chase Cancer Center Hematologist and Oncologist Stefan K. Barta, MD, MS, MRCP, researchers report that CNSi – identified at the time of an ARL diagnosis – does not appear to have an impact on overall survival. Dr. Barta's collaborators will present the findings at the 50th Annual Meeting ...
Moffitt Cancer Center instrumental in new clinical guidelines for cancer-related fatigue
2014-05-30
TAMPA, Fla. (May 30, 2014) – Fatigue is a debilitating problem for cancer patients undergoing treatment; however, it also poses a huge detriment after treatment and can significantly affect quality of life. Approximately 30 percent of cancer patients endure persistent fatigue for several years after treatment, according to an American Society of Clinical Oncology Expert Panel co-chaired by Paul Jacobsen, Ph.D., associate center director of Population Sciences at Moffitt Cancer Center.
ASCO created the panel to develop assessment, screening, and treatment guidelines for ...
First real time movies of the light-to-current conversion in an organic solar cell
2014-05-30
VIDEO:
Real time quantum simulation of the conversion of light into current in an organic solar cell composed of a polymer chain, and a Fullerene buckyball. The movie lasts for about...
Click here for more information.
Photovoltaic cells directly convert sun light into electricity and hence are key technological devices to meet one of the challenges that mankind has to face in this century: a sustainable and clean production of renewable energy. Organic solar cells, using polymeric ...
Research details how developing neurons sense a chemical cue
2014-05-30
Symmetry is an inherent part of development. As an embryo, an organism's brain and spinal cord, like the rest of its body, organize themselves into left and right halves as they grow. But a certain set of nerve cells do something unusual: they cross from one side to the other. New research in mice delves into the details of the molecular interactions that help guide these neurons toward this anatomical boundary.
In an embryo, a neuron's branches, or axons, have special structures on their tips that sense chemical cues telling them where to grow. The new findings, by ...
Study highlights side effects felt by BRCA mutation carriers after cancer risk-reducing procedure
2014-05-30
PHILADELPHIA — The majority of women with cancer causing BRCA1 and BRCA2 mutations experience sexual dysfunction, menopausal symptoms, cognitive and stress issues, and poor sleep following prophylactic removal of their Fallopian tubes and ovaries - a procedure known as risk-reducing salpingo-oophorectomy (RRSO) - according to results of a new study from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania. The team's findings, which reaffirm the need for a better understanding of how to manage long-term effects of the risk-reducing ...
Can narcissists be moved to show empathy?
2014-05-30
Researchers at the University of Surrey and the University of Southampton have investigated whether narcissists can elicit empathy for another person's suffering. It has been well documented that narcissists lack empathy, but why is that the case, and do they have the capacity to change that behavior? The research is published in Personality and Social Psychology Bulletin.
Characterizing narcissism
When we think of narcissism most of us can all think of a colleague, friend, or former significant other that would fit the description; "A bit full of themselves, self-centered, ...
Narcissists can feel empathy, research finds
2014-05-30
Narcissists tend to lack empathy, which can cause problems for themselves, the people around them and society in general. However, new research published today from the University of Surrey, suggests that with the right focus, people with narcissistic tendencies can feel empathy for another person's suffering. This may be important in helping to prevent the often violent or anti-social behaviours that some narcissists are prone to and the crimes that are committed as a result.
The research, published in Personality and Social Psychology Bulletin, studied participants ...
Eating prunes can help weight loss
2014-05-30
Research by the University of Liverpool has found that eating prunes as part of a weight control diet can improve weight loss.
Consumption of dried fruit is not readily recommended during weight loss despite evidence it enhances feelings of fullness.
However, a study by the University's Institute of Psychology, Health and Society of 100 overweight and obese low fibre consumers tested whether eating prunes as part of a weight loss diet helped or hindered weight control over a 12-week period.
It also examined if low fibre consumers could tolerate eating substantial ...
Cochrane review on use of rectal artesunate for severe malaria
2014-05-30
Researchers from the Cochrane Infectious Diseases Group, hosted at LSTM, conducted an independent review of the effects of pre-referral rectal artesunate for people with severe malaria, published in the Cochrane Library today. The review follows a large trial of rectal artesunate in 2009 which led the World Health Organization to recommend its use.
Severe malaria is a serious medical condition caused by infection with the Plasmodium parasite. It is treated by giving injections of antimalarial drugs, which need to be started as quickly as possible to reduce the risk of ...
One cell's meat is another cell's poison
2014-05-30
As a new therapeutic approach, Janus kinases are currently in the limelight of cancer research. The focus of interest is the protein JAK2. By inhibiting this protein one tries to cure chronic bone marrow diseases, such as myelofibrosis and chronic myeloid leukemia (CML).
Loss of JAK2 is advantageous for leukemia cells
Scientists working with Veronika Sexl at the Institute of Pharmacology and Toxicology may initiate a transformation of thought in regard of JAK2 inhibition. To simulate the human disease as accurately as possible, the scientists used a mouse leukemia ...